Literature DB >> 16639048

Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports.

William H Maisel1, Megan Moynahan, Bram D Zuckerman, Thomas P Gross, Oscar H Tovar, Donna-Bea Tillman, Daniel B Schultz.   

Abstract

CONTEXT: Pacemakers and implantable cardioverter-defibrillators (ICDs) are complex medical devices proven to reduce mortality in specific high-risk patient populations. It is not known if increasing device complexity is associated with decreased reliability.
OBJECTIVES: To analyze postapproval annual reports submitted to the US Food and Drug Administration (FDA) by manufacturers of pacemakers and ICDs to determine the reported number and rate of pacemaker and ICD malfunctions and to assess trends in device performance. DESIGN AND
SETTING: Pacemaker and ICD annual reports submitted to the FDA for the years 1990-2002 were reviewed. A pacemaker or ICD generator was defined as having malfunctioned if it was explanted due to an observed malfunction, returned to the manufacturer, and confirmed by the manufacturer to be functioning inappropriately. Leads and biventricular devices were not included in the study. Deaths were attributed to device malfunction only if they were witnessed, the malfunction immediately led to the death, and the malfunction was confirmed by the manufacturer. MAIN OUTCOME MEASURES: Number of implanted pacemaker and ICD generators; number of reported malfunctions; and annual malfunction replacement rates. Generator malfunction replacement rates were defined as the annual number of replacements due to confirmed malfunction divided by the annual number of implants.
RESULTS: During the study period, 2.25 million pacemakers and 415,780 ICDs were implanted in the United States. Overall, 17,323 devices (8834 pacemakers and 8489 ICDs) were explanted due to confirmed malfunction. Battery/capacitor abnormalities (4085 malfunctions [23.6%]) and electrical issues (4708 malfunctions [27.1%]) accounted for half of the total device failures. The annual pacemaker malfunction replacement rate per 1000 implants decreased significantly during the study, from a peak of 9.0 in 1993 to a low of 1.4 in 2002 (P = .006 for trend). In contrast, the ICD malfunction replacement rate per 1000 implants, after decreasing from 38.6 in 1993 to 7.9 in 1996, increased markedly during the latter half of the study, peaking in 2001 at 36.4 (P = .04 for trend). More than half of the reported ICD malfunctions occurred in the last 3 years of the study. Overall, the annual ICD malfunction replacement rate was significantly higher than the pacemaker malfunction replacement rate (mean [SD], 20.7 [11.6] vs 4.6 [2.2] replacements per 1000 implants; P<.001; rate ratio, 5.9 [95% confidence interval, 2.7-9.1]). Sixty-one deaths (30 pacemaker patients, 31 ICD patients) were attributable to device malfunction.
CONCLUSIONS: This study demonstrates that thousands of patients have been affected by pacemaker and ICD malfunctions, the pacemaker malfunction replacement rate has decreased, the ICD malfunction replacement rate increased during the latter half of the study, and the ICD malfunction replacement rate is significantly higher than that for pacemakers. Although pacemakers and ICDs are important life-sustaining devices that have saved many lives, careful monitoring of device performance is still required.

Entities:  

Mesh:

Year:  2006        PMID: 16639048     DOI: 10.1001/jama.295.16.1901

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  47 in total

1.  The effect of device advisories on implantable cardioverter-defibrillator therapy.

Authors:  Mitesh S Amin; Kenneth A Ellenbogen
Journal:  Curr Cardiol Rep       Date:  2010-09       Impact factor: 2.931

2.  Implantable cardioverter defibrillator: charge saver, not syncope saver!

Authors:  Diego Chemello; Anandaraja Subramanian; Sheila Watkins; Krishnakumar Nair; Kumaraswamy Nanthakumar
Journal:  Can J Cardiol       Date:  2010-11       Impact factor: 5.223

3.  Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention.

Authors:  Joshua R Silverstein; Demosthenes G Katritsis; Mark E Josephson
Journal:  Arrhythm Electrophysiol Rev       Date:  2012-09

Review 4.  [Annual report 2005 of the German pacemaker register].

Authors: 
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-09

Review 5.  [Perioperative management of patients with implanted pacemakers or cardioverter/defibrillators. Recommendations of the Austrian Society for Anaesthesiology, Resuscitation and Intensive Care Medicine, the Austrian Society for Cardiology and the Austrian Society for Surgery].

Authors:  H Gombotz; M Anelli Monti; N Leitgeb; M Nürnberg; B Strohmer
Journal:  Anaesthesist       Date:  2009-05       Impact factor: 1.041

6.  Fifty years of cardiac pacing: the dark side of the moon?

Authors:  C C de Cock
Journal:  Neth Heart J       Date:  2008-10       Impact factor: 2.380

7.  Gene therapy approaches to ventricular tachyarrhythmias.

Authors:  J Kevin Donahue; Tetsuo Sasano; Kamilla Kelemen
Journal:  J Electrocardiol       Date:  2007 Nov-Dec       Impact factor: 1.438

8.  A case of unexpected early battery depletion caused by lithium cluster formation in implantable cardioverter-defibrillator.

Authors:  Yusuke Hayashi; Masahiko Takagi; Jun Kakihara; Hiroaki Tatsumi; Doi Atsushi; Minoru Yoshiyama
Journal:  J Cardiol Cases       Date:  2017-04-15

9.  Molecular ablation of ventricular tachycardia after myocardial infarction.

Authors:  Tetsuo Sasano; Amy D McDonald; Kan Kikuchi; J Kevin Donahue
Journal:  Nat Med       Date:  2006-10-29       Impact factor: 53.440

10.  Impact of implantable cardioverter-defibrillator recalls on patients' anxiety, depression, and quality of life.

Authors:  Manish Undavia; Nathan E Goldstein; Pilar Cohen; Kamoltip Sinthawanarong; Magdalena Singson; Divaya Bhutani; Tracey Munson; Joseph Anthony Gomes; Avi Fischer; Davendra Mehta
Journal:  Pacing Clin Electrophysiol       Date:  2008-11       Impact factor: 1.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.